Table 1. Baseline characteristics of the... | American Society of Hematology

Table 1.

Baseline characteristics of the enrolled patients

Patient	At diagnosis						At study entry
Patient	Age (y)	Stage*	BM involved	CNS involved	LDH	First-line therapy	Time to failure (m)	Type of failure	Stage	Failure in BM	Failure in CNS	Bulky disease	Poor risk^†
P1	8	III	No	No	≥2 × ULN	FAB/LMB96-type	5	No CR	III	No	No	Yes	Yes
P2	8	IV	Yes	No	≥2 × ULN	FAB/LMB96-type	5	No CR	II	No	No	No	Yes
P3	10	IV	Yes	No	≥2 × ULN	FAB/LMB96-type	5	No CR	III	No	No	Yes	Yes
P4	11	III	No	No	≥2 × ULN	NHL/BFM95-type	5	Failure after CR	III	No	No	No	Yes
P5	11	IV	Yes	No	≥2 × ULN	NHL/BFM95-type	5	Failure after CR	IV	No	Yes	No	Yes
P6	9	III	No	No	<2 × ULN	NHL/BFM95-type	7	No CR	III	No	No	No	No
P7	9	IV	No	Yes	≥2 × ULN	FAB/LMB96-type	8	Failure after CR	IV	No	Yes	No	Yes
P8	10	IV	Yes	No	≥2 × ULN	FAB/LMB96-type	8	Failure after CR	III	No	No	No	Yes
P9	8	IV	Yes	Yes	≥2 × ULN	FAB/LMB96-type	7	Failure after CR	II	No	No	No	Yes
P10	7	III	No	No	≥2 × ULN	FAB/LMB96-type	3	No CR	III	No	No	Yes	Yes
P11	2.5	IV	Yes	No	≥2 × ULN	NHL/BFM95-type	5	Failure after CR	IV	Yes	Yes	Yes	Yes
P12	11	III	No	No	≥2 × ULN	NHL/BFM95-type	4	No CR	III	No	No	Yes	Yes
P13	3	IV	No	Yes	≥2 × ULN	FAB/LMB96-type	2	No CR	IV	Yes	Yes	Yes	Yes
P14	6	III	No	No	≥2 × ULN	NHL/BFM95-type	3	Failure after CR	III	No	No	No	Yes
P15	5	III	No	No	≥2 × ULN	NHL/BFM95-type	5	No CR	IV	No	Yes	No	Yes
P16	7	IV	Yes	Yes	≥2 × ULN	NHL/BFM95-type	9	Failure after CR	IV	Yes	Yes	No	Yes
P17	7	IV	No	Yes	<2 × ULN	NHL/BFM95-type	3	No CR	IV	No	Yes	No	Yes
P18	2	III	No	No	≥2 × ULN	NHL/BFM95-type	3	No CR	III	No	No	Yes	Yes
P19	5	IV	Yes	No	<2 × ULN	NHL/BFM95-type	9	Failure after CR	IV	No	Yes	No	No
P20	10	IV	Yes	Yes	≥2 × ULN	FAB/LMB96-type	5	Failure after CR	IV	No	Yes	No	Yes
P21	9	IV	Yes	Yes	≥2 × ULN	NHL/BFM95-type	4	No CR	IV	Yes	Yes	Yes	Yes
P22	8	III	No	No	≥2 × ULN	NHL/BFM95-type	8	Failure after CR	III	No	No	Yes	Yes
P23	12	III	No	No	≥2 × ULN	FAB/LMB96-type	5	No CR	II	No	No	No	Yes

Patient	At diagnosis						At study entry
Patient	Age (y)	Stage*	BM involved	CNS involved	LDH	First-line therapy	Time to failure (m)	Type of failure	Stage	Failure in BM	Failure in CNS	Bulky disease	Poor risk^†
P1	8	III	No	No	≥2 × ULN	FAB/LMB96-type	5	No CR	III	No	No	Yes	Yes
P2	8	IV	Yes	No	≥2 × ULN	FAB/LMB96-type	5	No CR	II	No	No	No	Yes
P3	10	IV	Yes	No	≥2 × ULN	FAB/LMB96-type	5	No CR	III	No	No	Yes	Yes
P4	11	III	No	No	≥2 × ULN	NHL/BFM95-type	5	Failure after CR	III	No	No	No	Yes
P5	11	IV	Yes	No	≥2 × ULN	NHL/BFM95-type	5	Failure after CR	IV	No	Yes	No	Yes
P6	9	III	No	No	<2 × ULN	NHL/BFM95-type	7	No CR	III	No	No	No	No
P7	9	IV	No	Yes	≥2 × ULN	FAB/LMB96-type	8	Failure after CR	IV	No	Yes	No	Yes
P8	10	IV	Yes	No	≥2 × ULN	FAB/LMB96-type	8	Failure after CR	III	No	No	No	Yes
P9	8	IV	Yes	Yes	≥2 × ULN	FAB/LMB96-type	7	Failure after CR	II	No	No	No	Yes
P10	7	III	No	No	≥2 × ULN	FAB/LMB96-type	3	No CR	III	No	No	Yes	Yes
P11	2.5	IV	Yes	No	≥2 × ULN	NHL/BFM95-type	5	Failure after CR	IV	Yes	Yes	Yes	Yes
P12	11	III	No	No	≥2 × ULN	NHL/BFM95-type	4	No CR	III	No	No	Yes	Yes
P13	3	IV	No	Yes	≥2 × ULN	FAB/LMB96-type	2	No CR	IV	Yes	Yes	Yes	Yes
P14	6	III	No	No	≥2 × ULN	NHL/BFM95-type	3	Failure after CR	III	No	No	No	Yes
P15	5	III	No	No	≥2 × ULN	NHL/BFM95-type	5	No CR	IV	No	Yes	No	Yes
P16	7	IV	Yes	Yes	≥2 × ULN	NHL/BFM95-type	9	Failure after CR	IV	Yes	Yes	No	Yes
P17	7	IV	No	Yes	<2 × ULN	NHL/BFM95-type	3	No CR	IV	No	Yes	No	Yes
P18	2	III	No	No	≥2 × ULN	NHL/BFM95-type	3	No CR	III	No	No	Yes	Yes
P19	5	IV	Yes	No	<2 × ULN	NHL/BFM95-type	9	Failure after CR	IV	No	Yes	No	No
P20	10	IV	Yes	Yes	≥2 × ULN	FAB/LMB96-type	5	Failure after CR	IV	No	Yes	No	Yes
P21	9	IV	Yes	Yes	≥2 × ULN	NHL/BFM95-type	4	No CR	IV	Yes	Yes	Yes	Yes
P22	8	III	No	No	≥2 × ULN	NHL/BFM95-type	8	Failure after CR	III	No	No	Yes	Yes
P23	12	III	No	No	≥2 × ULN	FAB/LMB96-type	5	No CR	II	No	No	No	Yes

BFM, Berlin-Frankfurt-Muenster; BM, bone marrow; FAB, French‐American‐British; LDH, lactate dehydrogenase; LMB, Lymphome Malins B; NHL, non-Hodgkin lymphoma; ULN, upper limit of normal.

Based on the International Pediatric Non-Hodgkin Lymphoma Staging System.

^†

Based on FAB poor-risk criteria.

View Large

This Feature Is Available To Subscribers Only